Trial design and oversight
DISEASE, PURGING
This was a single-center, ambispective cohort trial that received approval from the Shandong Provincial Hospital Affiliated to Shandong First Medical University (approval number 2018–239). In addition, the study was registered with the National Clinical Trial Center (ChiCTR2000030507). The research was carried out in accordance with the STROBE statement. The information relevant to this cohort study was collected from electronic medical records or follow-up record sheets, after purging personal information of all the patients. The Ethics Committee waived the need for informed consent by participants whose data were obtained from medical records before February 28, 2020 (the date of ethics approval), while written informed consent was obtained from patients (or their legal representatives) who were enrolled in the study after that date. All authors affirmed that the data and analyses in the trial were accurate and complete, and that the trial was conducted in a manner consistent with the study protocol. The statistical analysis was performed by Cheeloo College of Medicine, Shandong University. The Shandong Centers for Disease Control and Prevention served as a neutral third party which supported data management and quality control.